Triton X-100 : A poly(ethylene glycol) derivative that is poly(ethylene glycol) in which one of the terminal hydroxy groups has been converted into the corresponding p-(2,4,4-trimethylpentan-3-yl)phenyl ether. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 5590 |
| CHEMBL ID | 39763 |
| CHEBI ID | 177811 |
| CHEBI ID | 9750 |
| SCHEMBL ID | 33822 |
| MeSH ID | M0026938 |
| Synonym |
|---|
| 4-tert-octylphenol monoethoxylate |
| CHEBI:177811 |
| 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol |
| nsc-5259 |
| nsc5259 |
| ethanol,1,3,3-tetramethylbutyl)phenoxy]- |
| ethanol, octylphenoxy- |
| 2315-67-5 |
| peg 4-isooctylphenyl ether |
| peg 4-tert-octylphenyl ether |
| octoxynol-1 |
| peg (p-(1,1,3,3-tetramethylbutyl)phenyl) ether |
| BIO1_000963 |
| BIO1_000474 |
| BIO1_001452 |
| PDSP1_001087 |
| octoxinol |
| triton x |
| triton x-100 (tn) |
| octoxinol (inn) |
| octoxynol 9 (nf) |
| D05229 |
| PDSP2_001071 |
| 3,9,12,15,18,21,24,27,30-decaoxatriacontan-1-ol, 30-[p-(1,1,3,3-tetramethylbutyl)phenyl]- |
| triton x-102 |
| marlophen 820 |
| triton x 35 |
| triton x 405 |
| triton x-45 |
| triton x 705 |
| triton x 45 |
| triton x 305 |
| glycols, mono[p-(1,1,3,3-tetramethylbutyl)phenyl] ether |
| igepal ca 630 |
| triton x 165 |
| triton x 102 |
| nsc-406472 |
| hyonic pe-250 |
| neutronyx 605 |
| NCGC00091012-01 |
| triton x-100 |
| 9002-93-1 |
| CHEMBL39763 |
| triton,(-) |
| cas_5590 |
| nsc_5590 |
| triton,(+) |
| cas_118-96-7 |
| bdbm81480 |
| 2-(4-(1,1,3,3-tetramethylbutyl)phenoxy)ethanol |
| alpha-(p-(1,1,3,3-tetramethylbutyl)phenoxy)ethanol |
| 20cax7io75 , |
| ethanol, 2-(p-(1,1,3,3-tetramethylbutyl)phenoxy)- |
| nsc 5259 |
| ethanol, 2-(4-(1,1,3,3-tetramethylbutyl)phenoxy)- |
| octoxynol 1 |
| unii-20cax7io75 |
| tox21_202544 |
| NCGC00260093-01 |
| dsstox_gsid_34085 |
| dsstox_rid_79110 |
| tox21_111055 |
| dsstox_cid_14085 |
| cas-9002-93-1 |
| octoxinolum |
| CHEBI:9750 |
| FT-0689215 |
| FT-0673247 |
| 63869-93-2 |
| einecs 264-520-1 |
| 4-tert-octylphenyl (2-hydroxyethyl)ether |
| 2-(4-tert-octylphenoxy)ethanol |
| 2-[4-(1,1,3,3-tetramethylbutyl)phenoxy]ethanol |
| op1eo |
| octoxynol-1 [ii] |
| p-tert-octylphenyl (2-hydroxyethyl)ether |
| triton x-15 |
| octoxynol 1 [vandf] |
| triton x-15 surfactant |
| igepal ca-210 |
| octoxynol-1 [inci] |
| SCHEMBL33822 |
| DTXSID1058680 |
| 2-[4-(2,4,4-trimethyl-2-pentanyl)phenoxy]ethanol |
| STL451484 |
| mfcd00132505 |
| 2-(4-(2,4,4-trimethylpentan-2-yl)phenoxy)ethanol |
| AS-68067 |
| 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethan-1-ol |
| ethanol, 2-[4-(1,1,3,3-tetramethylbutyl)phenoxy]- |
| J-015013 |
| 4-iso-octylphenol-mono-ethoxylate 10 microg/ml in acetone |
| JYCQQPHGFMYQCF-UHFFFAOYSA-N |
| Q27253450 |
| AT25387 |
| CS-0449852 |
| 2-(4-(2,4,4-trimethylpentan-2-yl)phenoxy)ethan-1-ol |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Class | Description |
|---|---|
| alkylbenzene | A monocyclic arene that is benzene substituted with one or more alkyl groups. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Cruzipain | Trypanosoma cruzi | Potency | 15.8489 | 0.0020 | 14.6779 | 39.8107 | AID1476 |
| hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 1.9387 | 3.1890 | 29.8841 | 59.4836 | AID1224846 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 18.8516 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
| TDP1 protein | Homo sapiens (human) | Potency | 9.5037 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 14.4318 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
| AR protein | Homo sapiens (human) | Potency | 10.9127 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID743035; AID743042; AID743054; AID743063 |
| caspase 7, apoptosis-related cysteine protease | Homo sapiens (human) | Potency | 68.1713 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 43.0132 | 0.0006 | 57.9133 | 22,387.1992 | AID1259378 |
| progesterone receptor | Homo sapiens (human) | Potency | 48.2616 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 3.5481 | 0.0123 | 7.9835 | 43.2770 | AID1346984 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 10.8394 | 0.0002 | 14.3764 | 60.0339 | AID588533; AID720691; AID720692 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 37.5993 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 8.7686 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 61.3056 | 0.3758 | 27.4851 | 61.6524 | AID743217 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 9.2120 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982; AID720659 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 18.7183 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID1259248; AID743069; AID743075; AID743078; AID743079; AID743080; AID743091 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 30.7256 | 0.0010 | 19.4141 | 70.9645 | AID743140 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 22.0725 | 0.0237 | 23.2282 | 63.5986 | AID743222; AID743241 |
| caspase-3 | Homo sapiens (human) | Potency | 68.1713 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 34.8082 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 51.5822 | 0.0578 | 21.1097 | 61.2679 | AID1159528 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 35.4813 | 0.0178 | 9.6374 | 44.6684 | AID588834 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 37.0455 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 61.3056 | 0.0420 | 27.3789 | 61.6448 | AID743210 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 24.5452 | 0.0006 | 27.2152 | 1,122.0200 | AID651741; AID743202; AID743219 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 35.4813 | 0.0079 | 8.2332 | 1,122.0200 | AID2546 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 40.5334 | 0.0056 | 12.3677 | 36.1254 | AID624032 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 25.1189 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 31.6228 | 0.0316 | 10.2792 | 39.8107 | AID884; AID885 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 10.8044 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 43.0132 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 10.8044 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Nuclear receptor ROR-gamma | Homo sapiens (human) | Potency | 42.1632 | 0.0266 | 22.4482 | 66.8242 | AID651802 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 13.3332 | 0.0119 | 17.9420 | 71.5630 | AID651632 |
| Ataxin-2 | Homo sapiens (human) | Potency | 13.3332 | 0.0119 | 12.2221 | 68.7989 | AID651632 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID333173 | Antiproliferative activity against human HaCaT cells assessed as [3H]thymidine incorporation at 5 uM after 24 hrs | 2004 | Journal of natural products, Sep, Volume: 67, Issue:9 | Potential antipsoriatic avarol derivatives as antioxidants and inhibitors of PGE(2) generation and proliferation in the HaCaT cell line. |
| AID192022 | Compound was evaluated for the amount of protein solubilized, expressed as percentage weight of freeze-dried microsomes (20 mg) of rat liver | 1998 | Bioorganic & medicinal chemistry letters, Jun-16, Volume: 8, Issue:12 | A new class of sulfoxide surfactants derived from Tris. Synthesis and preliminary assessments of their properties. |
| AID333177 | Cytotoxicity against human HaCaT cells assessed as LDH release at 5 uM after 24 hrs | 2004 | Journal of natural products, Sep, Volume: 67, Issue:9 | Potential antipsoriatic avarol derivatives as antioxidants and inhibitors of PGE(2) generation and proliferation in the HaCaT cell line. |
| AID333171 | Inhibition of TPA-induced ROS production in human neutrophils at 5 uM by chemiluminescence | 2004 | Journal of natural products, Sep, Volume: 67, Issue:9 | Potential antipsoriatic avarol derivatives as antioxidants and inhibitors of PGE(2) generation and proliferation in the HaCaT cell line. |
| AID192023 | Compound was evaluated for the amount of protein solubilized, expressed as percentage weight of freeze-dried mitochondria (20 mg) of rat liver | 1998 | Bioorganic & medicinal chemistry letters, Jun-16, Volume: 8, Issue:12 | A new class of sulfoxide surfactants derived from Tris. Synthesis and preliminary assessments of their properties. |
| AID192024 | Compound was evaluated for the amount of protein solubilized, expressed as percentage weight of freeze-dried nuclear membrane (100 mg) of rat liver | 1998 | Bioorganic & medicinal chemistry letters, Jun-16, Volume: 8, Issue:12 | A new class of sulfoxide surfactants derived from Tris. Synthesis and preliminary assessments of their properties. |
| AID333175 | Inhibition of PGE2 production in human HaCaT cells at 5 uM after 24 hrs by RIA | 2004 | Journal of natural products, Sep, Volume: 67, Issue:9 | Potential antipsoriatic avarol derivatives as antioxidants and inhibitors of PGE(2) generation and proliferation in the HaCaT cell line. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (53.45) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||